Response of lipoprotein(a) levels to therapeutic life-style change in obese African-Americans

Atherosclerosis

Volumn 172, Issue 1, 2004, Pages 155-160

  Randall, Otelio S ^a   Feseha, Habteab B ^a   Illoh, Kachi ^a   Xu, Shichen ^a   Ketete, Muluemebet ^a   Kwagyan, John ^a   Tilghman, Carl ^a   Wrenn, Michelle ^a  

^a HOWARD UNIVERSITY HOSPITAL   (United States)

Author keywords

African American; Cardiovascular risk; Diet; Exercise; Lipoprotein(a) (Lp(a)); Therapeutic lifestyle change

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY ATHEROSCLEROSIS; EXERCISE; FEMALE; HUMAN; LIFESTYLE; LIPID DIET; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0347985749     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2003.09.017     Document Type: Article

References (35)

1. Bachorik P, Rifkins B, Kwiterovich P. Lipids and dyslipoproteinemia. In: Henry JB, editor. Clinical diagnosis and management by laboratory methods. 19th ed. Philadelphia: WB Saunders; 1996. p. 208-36.
2. Ginsberg H, Goldberg I. Disorders of lipoprotein metabolism. In: Braunwald E, Fauci AS, Kasper DC, Hauser SL, Lonpo DC, Jameson JL, editors. Harrison's principles of internal medicine. 15th ed. New York: McGraw-Hill; 2007. p. 2245-57.
3. Scanu A.M. Atherothrombogenicity of lipoprotein(a): the debate. Am. J. Cardiol. 82:1998;26Q-33Q.
4. Dangas G., Ambrose J.A., D'Agate D.J., Shao J.H., Chockalingham S., Levine D.et al. Correlation of serum lipoprotein(a) with the angiographic and clinical presentation of coronary artery disease. Am. J. Cardiol. 83:1999;583-585.
5. Loscalzo J., Weinfeld M., Fless G.M., Scanu A.M. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis. 10:1990;240.
6. Palabrica T.M., Liu A.C., Aronovitz M.J., Furie B., Lawn R.M., Furie B.C. Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nat. Med. 1:1995;256.
7. Zioncheck T.F., Powell L.M., Rice G.C., Eaton D.L., Lawn R.M. Interaction of recombinant apolipoprotein(a) and lipoprotein(a) with macrophages. J. Clin. Invest. 87:1991;767.
8. Rosengren A., Wilhelmsen L., Ericksson E., Risberg B., Wedel H. Lipoprotein(a) and coronary heart disease a perspective case-control study in a general population sample of middle aged men. Br. Med. J. 301:1990;1248-1251.
9. Dahlen GH. Potential significance of Lp(a) lipoprotein. In: Bearn AG, editor. Genetics of coronary heart disease. Oslo: Institute of Medical Genetics; 1992. p. 75-88.
10. Sigurdsson G., Baldursdottir A., Sigvaldason H., Agnarsson U., Thorgeirsson G., Sigfusson N. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am. J. Cardiol. 69:1992;1251-1254.
11. Jauhiainen M., Koskinen P., Ehnholm C., Frick M.H., Manttari M., Manninen V.et al. Lipoprotein(a) and coronary heart disease: a nested case-control study of Helsinki Heart Study Participants. Atherosclerosis. 89:1991;59-67.
12. Ridker P.M., Hennekens C.H., Stampfer M.J. A prospective study of lipoprotein(a) and risk of myocardial infarction. Circulation. 88(Suppl):1993;1-261.
13. Schaefer E.J., Lamon-Fava S., Jenner J.L., McNamara J.R., Ordovas J.M., Davis C.E.et al. Lipoprotein(a) levels and risk of coronary heart disease in men. The lipids research clinics coronary primary preventive trial. J. Am. Med. Assoc. 271:1994;999-1003.
14. Marburger C., Hambrect R., Niebauer J., Schoeppenthau M., Scheffler E., Hauer K.et al. Association between lipoprotein(a) and progression of coronary artery disease in middle-aged men. Am. J. Cardiol. 73:1994;742-746.
15. Corsetti J.P., Sterry J.A., Sparks J.D., Sparks C.E., Weintraub M. Effect of weight loss on serum lipoprotein(a) concentrations in obese population. Clin. Chem. 37:1991;1191-1195.
16. Drowatzky K.L., Durstine J.L., Irwin M.L., Moore C.G., Davis P.G., Hand G.A.et al. The association between physical activity, cardiorespiratory fitness, and lipoprotein(a) concentrations in tri-ethnic sample of women: The cross-cultural activity participation study. Vasc. Med. 6:2001;15-21.
17. Marcovina S.M., Albers J.J., Wijsman E., Zhang Z., Chapman N.H., Kennedy H. Differences in Lp(a) concentration and apo(a) polymorphs between black and white Americans. J. Lipid. Res. 37:1996;2569.
18. Harjai K.J. Potential new cardiovascular risk factors: left ventricular hypertrophy, homocysteine, lipoprotein(a), triglycerides, oxidative stress, and fibrinogen. Ann. Intern. Med. 131:1999;376-386.
19. Randall O.S., Feseha H.B., Retta T.M., Bettencourt C.N., Xu S., Ketete M.et al. Effects of a low-calorie, low-salt diet and treadmill exercise on atherosclerotic risk factors in obese African-American women. Am. J. Cardiol. 89:2002;1311-1313.
20. Randall OS, Randall D. Menu for life: African-Americans get healthy, eat well, lose weight and live beautifully. New York (NY): Random House Inc.; 2003. p. 22.
21. Corsetti J.P., Sterry J.A., Sparks J.D., Sparks C.E., Weintraub M. Effect of weight loss on serum lipoprotein(a) in an Obese population. Clin. Chem. 37:1991;1191-1195.
22. Bostom A.G., Gagnon D.R., Cupples L.A., Wilson P.W.F., Jenner J.L., Ordovas J.M.et al. A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women: The Framingham heart study. Circulation. 90:1994;1688-1695.
23. Myers J., Prakash M., Froelicher V., Do D., Partington S., Atwood J.E. Exercise capacity and mortality among men referred for exercise testing. N. Engl. J. Med. 346:2002;793-801.
24. Sandvik L., Erikssen J., Thaulow E., Erickssen G., Mundal R., Rodahl K. Physical fitness as a predictor of mortality among healthy, middle aged Norwegian men. N. Engl. J. Med. 328:1993;533-537.
25. Paffenbarger R., Hyde R., Wing A., Lee I.-M., Jung D., Kampert J. The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. N. Engl. J. Med. 328:1993;538-545.
26. Berg A., Halle M., Franz I., Keul J. Physical activity and lipoprotein metabolism: epidemiological evidence and clinical trials. Eur. J. Med. Res. 2:1997;259-264.
27. Mackinnon L.T., Hubinger L.M. Effects of exercise on lipoprotein(a). Sports Med. 28:1999;11-24.
28. Holme I., Urdal P., Anderssen S., Hjermann I. Exercise induced increase in lipoprotein(a). Atherosclerosis. 122:1996;97-104.
29. Halle M., Berg A., Stein V.T., Konig D., Baumstark M.W., Keul J. Lipoprotein(a) in edurance athletes and sedentary controls. Med. Sci. Sports Exerc. 28:1996;962-966.
30. Byrne D.J., Jagroop I.A., Montgomery H.E., Thomas M., Mikhailidis D.P., Milton N.G.et al. Lipoprotein(a) does not participate in the early acute phase response to training or extreme physical activity and is unlikely to enhance any associated immediate cardiovascular risk. J. Clin. Pathol. 55:2002;280-285.
31. Hershkovitz E., Belotserkovsky O., Limony Y., Leiberman E., Shany S., Phillip M. Increase of serum lipoprotein(a) levels during growth hormone therapy in normal short children. Eur. J. Pediatr. 157:1998;4-7.
32. Takarada Y., Nakamura Y., Aruga S., Onda T., Miyazaki S., Ishii N. Rapid increase in plasma growth hormone after low intensity resistance exercise with vascular occlusion. J. Appl. Physiol. 88:2000;61-65.
33. Kraemer R.R., Kilgore J.L., Kraemer G.R., Castracane V.D. Growth hormone, IGF-I and testosterone response to resistive exercise. Med. Sci. Sports Exerc. 24:1992;1346-1352.
34. Froelich J. Lipoproteins and homocysteine as risk factors for atherosclerosis: assessment and treatment. Can. J. Cardiol. 11(Suppl C):1995;18C-23C.
35. Scanu A.M. Lipoprotein(a): a genetic risk factor for premature coronary heart disease. J. Am. Med. Assoc. 267:1992;3326-3329.